Publication Name	World Journal of Gastroenterology
Manuscript ID	10785
Country	China

Received	2014-04-19 14:29
Peer-Review Started	2014-04-19 18:43
To Make the First Decision	2014-05-13 20:02
Return for Revision	2014-05-21 08:27
Revised	2014-06-12 00:00
Second Decision	2014-07-11 17:04
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-07-11 17:13
Articles in Press	2014-07-11 17:30
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-07-23 22:07
Typeset the Manuscript	2014-12-08 20:06
Publish the Manuscript Online	2014-12-20 19:42

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Meta-Analysis
Article Title	Efficacy and safety of gemcitabine-based combination chemotherapy in advanced biliary tract cancer: A meta-analysis
Manuscript Source	Unsolicited Manuscript
All Author List	Heng Liu, Qi-Di Zhang, Zheng-Hong Li, Qing-Qing Zhang and Lun-Gen Lu
Funding Agency and Grant Number
Corresponding Author	Lun-Gen Lu, MD, Professor, Chief, Department of Gastroenterology, Shanghai First People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai 200080, China. lungenlu1965@163.com
Key Words	Biliary tract cancer; Combination chemotherapy; Gemcitabine; Meta-analysis; Randomized trial
Core Tip	In this meta-analysis, we evaluated the efficacy and safety of gemcitabine-based combination chemotherapy compared with other regimens for the treatment of advanced BTC. Seven randomized trials were selected and included in the final analysis. The overall analyses revealed that patients treated with Gem-based combination chemotherapy had significantly higher DRR, a longer PFS and a longer OS. A higher incidence of grade 3-4 hematological toxicities: including leukopenia, anemia, neutropenia in the Gem-based combination chemotherapy group compared with the Gem monotherapy or non-Gem-based chemotherapy group. However, all severe hematological toxicities are infrequent and reversible. Therefore, Gem-based combination chemotherapy should be considered a standard first-line treatment for advanced BTC.
Publish Date	2014-12-20 19:42
Citation	Liu H, Zhang QD, Li ZH, Zhang QQ, Lu LG. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: A meta-analysis. World J Gastroenterol 2014; 20(47): 18001-18012
URL	http://www.wjgnet.com/1007-9327/full/v20/i47/18001.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i47.18001

Full Article (PDF)	WJG-20-18001.pdf
Full Article (Word)	WJG-20-18001.doc
Manuscript File	10785-Review.docx
Answering Reviewers	10785-Answering reviewers.pdf
Copyright License Agreement	10785-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	Editing_Certificate_20140419095256.pdf
Peer-review Report	10785-Peer review.pdf
Scientific Misconduct Check	10785-CrossCheck.jpg
Scientific Editor Work List	10785-Scientific editor work list.pdf